title: The Immunotherapy Roadmap.
abstract: As new active agents are discovered and approved, it is clear that combinations of these immunotherapies will be needed to reject most human cancers. The era of personalized patient tumor analysis has arrived just in time to guide these combinations.
authors.affiliation: Surgery Branch, National Cancer Institute, Bethesda, Maryland. jamesyang@mail.nih.gov.
authors.forename: James C
authors.initials: JC
authors.lastname: Yang
mesh_terms: D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms